Experts discuss the integration of GLP-1 receptor agonists in treating neuroendocrine tumors, highlighting safety concerns ...

Brendon Yee, PhD, professor and respiratory and sleep physician, Woolcock Institute of Medical Research, discusses the success of ALKS 2680, an investigational oral selective orexin 2 receptor agonist ...

GLP-1 receptor agonists are linked to a 55% reduction in mortality risk in women with ovarian cancer, based on a retrospective cohort study. The study utilized data from the TriNetX Research Network, ...

Patients with narcolepsy type 1 have hypersomnolence caused by a loss of orexin-producing neurons. New research findings on oveporexton, a highly selective oral orexin receptor 2 agonist, in these ...

ALK Tyrosine Kinase Inhibitors Induced Weight Gain: More Refined Definition of Weight Gain, Glucagon-Like Peptide-1 Agonist Treatment, and Therapeutic Drug Monitoring of ALK+ Non–Small Cell Lung ...

By Tarun Sai Lomte Real-world data from over 14,000 Italian adults reveal that GLP-1 receptor agonists can induce remission ...

Narcolepsy type 1 is a disorder of hypersomnolence caused by a loss of orexin neurons, which results in low orexin levels in the brain. In this phase 2, randomized, placebo-controlled trial, ...